Enhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington’s disease
- 4 March 2019
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 76 (12) , 2449-2461
Abstract
Huntington’s disease (HD) is a hereditary and fatal disease causing profound neurodegeneration. Deficits in cerebral energy and neurotransmitter metabolism have been suggested to play a central role in the neuronal dysfunction and death associated with HD. The branched-chain amino acids (BCAAs), leucine, isoleucine and valine, are important for cerebral nitrogen homeostasis, neurotransmitter recycling and can be utilized as energy substrates in the tricarboxylic acid (TCA) cycle. Reduced levels of BCAAs in HD have been validated by several reports. However, it is still unknown how cerebral BCAA metabolism is regulated in HD. Here we investigate the metabolism of leucine and isoleucine in the R6/2 mouse model of HD. Acutely isolated cerebral cortical and striatal slices of control and R6/2 mice were incubated in media containing 15N- or 13C-labeled leucine or isoleucine and slice extracts were analyzed by gas chromatography–mass spectrometry (GC–MS) to determine isotopic enrichment of derived metabolites. Elevated BCAA transamination was found from incubations with [15N]leucine and [15N]isoleucine, in both cerebral cortical and striatal slices of R6/2 mice compared to controls. Metabolism of [U-13C]leucine and [U-13C]isoleucine, entering oxidative metabolism as acetyl CoA, was maintained in R6/2 mice. However, metabolism of [U-13C]isoleucine, entering the TCA cycle as succinyl CoA, was elevated in both cerebral cortical and striatal slices of R6/2 mice, suggesting enhanced metabolic flux via this anaplerotic pathway. To support the metabolic studies, expression of enzymes in the BCAA metabolic pathway was assessed from a proteomic resource. Several enzymes related to BCAA metabolism were found to exhibit augmented expression in the R6/2 brain, particularly related to isoleucine metabolism, suggesting an increase in the BCAA metabolic machinery. Our results show that the capacity for cerebral BCAA metabolism, predominantly of isoleucine, is amplified in the R6/2 brain and indicates that perturbations in cerebral BCAA homeostasis could have functional consequences for HD pathology.Keywords
Funding Information
- Aase og Ejnar Danielsens Fond (10-002028)
- Augustinus Fonden (17-4115)
This publication has 63 references indexed in Scilit:
- Early Alterations of Brain Cellular Energy Homeostasis in Huntington Disease ModelsJournal of Biological Chemistry, 2012
- Cortical Metabolites as Biomarkers in the R6/2 Model of Huntington's DiseaseJournal of Cerebral Blood Flow & Metabolism, 2011
- Metabolite profiles and the risk of developing diabetesNature Medicine, 2011
- Energy deficit in Huntington disease: why it mattersJournal of Clinical Investigation, 2011
- Mitochondrial loss, dysfunction and altered dynamics in Huntington's diseaseHuman Molecular Genetics, 2010
- Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease ProgressionPLOS ONE, 2007
- Selective defect of in vivo glycolysis in early Huntington's disease striatumProceedings of the National Academy of Sciences, 2007
- Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo1H NMR spectroscopyJournal of Neurochemistry, 2006
- The glutamate/GABA‐glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transferJournal of Neurochemistry, 2006
- [ 15 N] leucine as a source of [ 15 N] glutamate in organotypic cerebellar explantsBiochemical and Biophysical Research Communications, 1983